Transplantation of allogenic fetal membrane-derived mesenchymal stem cells protect kidney

间充质干细胞（MSC）是治疗肾脏疾病的有吸引力的治疗细胞来源。MSC给药已被证明可改善肾功能，尽管其潜在机制尚不完全清楚。我们最近发现，同种异体胎儿膜源性间充质干细胞（FM-MSC）在实验性肾小球肾炎模型中具有肾脏保护作用，该细胞无创大量可用。在这里，我们研究了同种异体FM-MSC给药是否可以保护肾脏免受抗thy -1肾小球肾炎或缺血/再灌注（I/ R）损伤。组织学检查显示，给予FM-MSC可显著抑制肾小球损伤或I/ R损伤。给药的FM-MSC很少在肾脏中观察到，但给药的FM-MSC增加了血清IL-10水平。此外，利用抗IL-10中和抗体可消除FM-MSC的肾保护作用，提示IL-10可能是保护大鼠肾损伤的候选因子之一。我们得出结论，同种异体骨髓间充质干细胞移植是治疗肾脏疾病的有效治疗策略。

Mesenchymal stem cell(MSC) is an attractive therapeutic cell source for treating renal diseases. MSC administration has been shown to improve renal function, although underlying mechanisms are incompletely understood. We recently showed that allogenic fetal membrane-derived MSC(FM-MSC), which is available non-invasively in large amounts, had renoprotective effect in an experimental glomerulonephritis model. Here, we investigated whether allogenic FM-MSC administration could protect kidneys from anti-Thy-1 glomerulonephritis or ischemia/ reperfusion(I/ R) injury. Histological examination revealed that FM-MSC administration significantly suppressed glomerular injury or I/ R injury. Administered FM-MSC were rarely observed in kidneys, but administration of FM-MSC increased serum IL-10 levels. In addition, renoprotective effects of FM-MSC were abolished by using anti-IL-10 neutralization antibody, suggesting that IL-10 would be one of the candidate factors to protect rat kidney from kidney injury. We concluded that allogenic FM-MSC transplantation is a potent therapeutic strategy for the treatment of kidney diseases.